Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016

Details for Mechanism ID: 13559
Country/Region: Angola
Year: 2016
Main Partner: Johns Hopkins University
Main Partner Program: JHPIEGO
Organizational Type: University
Funding Agency: USAID
Total Funding: $927,803 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $24,720
Care: Pediatric Care and Support (PDCS) $15,465
Strategic Information (HVSI) $47,950
Health Systems Strengthening (OHSS) $133,982
Prevention: HIV Testing and Counseling (HVCT) $250,067
Treatment: Adult Treatment (HTXS) $338,935
Treatment: Pediatric Treatment (PDTX) $116,684
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 8,796
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 6,043
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 936
HTC_TST_TA Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 682
HTC_TST_TA Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 16,457
HTC_TST_TA Service Delivery Point (Facility): Index testing 2017 653
HTC_TST_TA Service Delivery Point (Facility): Inpatient 2017 151
HTC_TST_TA Service Delivery Point (Facility): Other PITC 2017 1,801
HTC_TST_TA Service Delivery Point (Facility): Outpatient 2017 161
HTC_TST_TA Service Delivery Point (Facility): Pediatric 2017 49
HTC_TST_TA Service Delivery Point (Facility): PMTCT 2017 2,178
HTC_TST_TA Service Delivery Point (Facility): TB Clinics 2017 2,205
HTC_TST_TA Service Delivery Point (Facility): VCT 2017 9,259
HTC_TST_TA Sum of Aggregated Age/Sex 15+ 2017 14,839
HTC_TST_TA Sum of Aggregated Age/Sex <15 2017 1,618
HTC_TST_TA Sum of Aggregated Age/Sex disaggregates 2017 16,457
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 1,054
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 611
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive <15 Female 2017 125
HTC_TST_TA Test Result by Aggregated Age and Sex: Positive <15 Male 2017 112
TX_CURR_TA Aggregated Age/Sex: 15+ Female 2017 5,172
TX_CURR_TA Aggregated Age/Sex: 15+ Male 2017 2,509
TX_CURR_TA Aggregated Age/Sex: <15 Female 2017 675
TX_CURR_TA Aggregated Age/Sex: <15 Male 2017 646
TX_CURR_TA Number of adults and children receiving antiretroviral therapy (ART) 2017 9,002
TX_CURR_TA Sum of Aggregated Age/Sex 15+ 2017 7,681
TX_CURR_TA Sum of Aggregated Age/Sex <15 2017 1,321
TX_CURR_TA Sum of Aggregated Age/Sex disaggregates 2017 9,002
TX_NEW_TA Aggregated Grouping by Age/Sex: 15+ Female 2017 1,111
TX_NEW_TA Aggregated Grouping by Age/Sex: 15+ Male 2017 536
TX_NEW_TA Aggregated Grouping by Age/Sex: <15 Female 2017 153
TX_NEW_TA Aggregated Grouping by Age/Sex: <15 Male 2017 137
TX_NEW_TA Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 1,937
TX_NEW_TA Sum of Aggregated Age/Sex disaggregates 2017 1,937
TX_RET_TA Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 534
TX_RET_TA Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 427
TX_RET_TA Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 242
TX_RET_TA Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 194
TX_RET_TA Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 40
TX_RET_TA Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 32
TX_RET_TA Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 38
TX_RET_TA Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 32
TX_RET_TA Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 685
TX_RET_TA Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 854